Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01721070 · ClinicalTrials.gov registry record · Phase 1
Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics
A Phase 1 study, sponsored by Talphera.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01721070 is a Phase 1 study that has completed, run by Talphera. The registered enrollment target is 19 participants.
The verdict
NCT01721070, a Phase 1 study, has completed, sponsored by Talphera.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
Evaluate the effect of taking ketoconazole on sufentanil plasma concentrations following sublingual administration of sufentanil NanoTab.
Interventions
- DRUG Sufentanil NanoTab (SUF NT) 15 mcg
- DRUG Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01721070
The ClinicalTrials.gov registry entry for NCT01721070 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Talphera, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sufentanil NanoTab (SUF NT) 15 mcg is the first listed.
NCT01721070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01721070 about?
NCT01721070 is a clinical study titled "Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics". Evaluate the effect of taking ketoconazole on sufentanil plasma concentrations following sublingual administration of sufentanil NanoTab.
What is the current status of trial NCT01721070?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2012-11. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01721070?
The interventions under investigation include: Sufentanil NanoTab (SUF NT) 15 mcg (DRUG), Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg (DRUG).
Who is sponsoring clinical trial NCT01721070?
This trial is sponsored by Talphera, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.